Welcome to our dedicated page for Pao Group news (Ticker: PAOG), a resource for investors and traders seeking the latest updates and insights on Pao Group stock.
PAO Group, Inc. reports corporate developments for an OTC-traded holding company focused on legal-rights support and legal-practice referral activities. Recent company news includes leadership changes, rescinded material agreements, preferred-share capital-structure items, shareholder voting matters, governance updates, and operating and financial results.
Historical announcements also covered the company’s cannabis and CBD activities, including RX Branded CBD nutraceutical products, CBD intellectual property associated with a patented extraction method, and RespRx, a CBD formulation discussed for respiratory conditions such as COPD.
PAO Group (OTC: PAOG) announced the resignation of CEO James Schramm and the formal rescission of the Purchase and Sale Agreement dated July 21, 2025, effective March 18, 2026. Under the rescission, Law90, LLC will be returned to James Schramm and 3,510,000 Preferred C shares will be returned to James C. DiPrima.
Mr. Schramm intends to convey Law90 to Green Stream Holdings, Inc. The company said it remains focused on advancing strategic initiatives, strengthening operational continuity, and positioning PAOG for long-term growth. Additional leadership and corporate updates will be provided as appropriate.
PAO Group (PAOG:OTC) announced the launch of its AI Positioning Program on November 19, 2025, a proprietary AI system that the company says can boost attorney case performance.
The release contrasts a traditional $10,000 verdict baseline with attorney outcomes using the platform that the company describes as having the potential to exceed $800,000 on the same case. LAW90 said the program leverages data-driven AI strategy, predictive modeling, and deep case analysis and is exclusive to LAW90 members.
LAW90 also announced an expansion into the Texas legal market with membership pre-sales beginning January 2026, and a national hiring initiative for 2026 to recruit National Marketing Executives to support marketing, memberships, and the Specialized Litigator Award rollout.
PAO Group Inc (OTC:PAOG) has announced a significant leadership change with the appointment of James Schramm as its new Chief Executive Officer, while former CEO James C DiPrima will continue as Chief Financial Officer. The company is pivoting its business strategy to follow Schramm's successful model from LAW 90, which has provided legal services since 1995 through "The Legal Helpline" across various practice areas including Personal Injury, Medical Malpractice, and Family Law.
The transition involves a planned acquisition of LAW 90 through a share purchase agreement, aiming to transform PAO Group into a publicly traded legal services provider. The strategic move is expected to provide access to new capital markets and accelerate growth opportunities.
PAO Group Inc (OTC:PAOG) has announced the acquisition of 100% membership interest in Law 90, LLC, a Nevada-based legal services company established in 1995. Law 90 specializes in various legal services including Personal Injury, Medical Malpractice, Family Law, Criminal Defence, Probate/Wills, and Corporate/Contract Law.
The acquisition will be executed through a share purchase agreement, with Law 90's current management team expected to join PAOG's leadership and add a new Board member. The company is considering a potential name change. Law 90's Founder and Managing Partner, James Scramm, views this business combination as a strategic move to access new capital markets and expand operations.
PAO Group, Inc. (OTC Pink: PAOG) announced its expectations for increased market visibility for its RX Branded CBD Nutraceuticals. This is attributed to the launch of the USMJ Ecommerce expansion campaign. PAOG currently markets its CBD products via North American Cannabis Inc.'s ecommerce site. The company is also collaborating with Puration, Inc. to develop additional CBD Nutraceuticals. Notably, PAOG holds a U.S. Patent for a cannabis extraction process and is working on a CBD formulation for Chronic Obstructive Pulmonary Disease (COPD) under the brand name RespRx.
PAO Group, Inc. (OTC Pink: PAOG) provided a strategic update on its CBD pharmaceutical and nutraceutical initiatives. The company is advancing a cannabis extract therapy for respiratory disorders, particularly COPD, which has a projected market size of $14.1 billion by 2025. They have engaged a Contract Research Organization (CRO) to seek FDA approval for their COPD treatment, RespRx. PAOG also launched a range of CBD nutraceutical products and plans further development with Puration, Inc. under its RX label. The path to revenue encompasses significant challenges and expenses.
PAO Group, Inc. (OTC Pink: PAOG) provided a strategic update on its CBD pharmaceutical and nutraceutical initiatives. The company is developing a CBD-based therapy for respiratory diseases, including COPD, targeting a $14.1B market by 2025. Favorable preclinical results support the potential of their flagship product, RespRx, with a CRO engaged for FDA approval processes.
Additionally, PAOG is launching a line of CBD nutraceutical products, aiming for quick revenue growth. The company anticipates a partnership announcement with Puration, Inc. for further product development.
PAO Group, Inc. (OTC Pink: PAOG) highlighted research indicating that CBDA and CBGA, compounds found in hemp, can block a critical step the Covid virus uses to infect humans. These compounds inhibit the binding of the virus's spike proteins to human cells. PAOG holds intellectual property related to CBD extraction and is developing treatments for respiratory conditions, including Chronic Obstructive Pulmonary Disease (COPD), under the brand name RespRx. The company plans to publish a strategic update on January 28, 2022.
PAO Group, Inc. (OTC Pink: PAOG) has confirmed the development of CBD nutraceutical products for Puration, Inc. (OTC Pink: PURA), which is now focusing on an industrial hemp business cooperative named Farmersville Hemp. PURA has secured its first clients contributing to 2022 revenue goals, forecasting revenue of $1 million with potential growth to $10 million. PAOG owns a patented extraction method and is developing pharmaceutical and nutraceutical treatments. A partnership between PAOG and PURA will lead to CBD products under the Farmersville Hemp brand.
PAO Group, Inc. (OTC Pink: PAOG) announced that its RX branded full spectrum CBD products are now for sale at www.usmj.com. These products, which include CBD soft gels, tinctures, and muscle salves, utilize PAOG's proprietary extraction technology and have received positive consumer feedback. Additionally, the company has recently acquired an exclusive license for a CBD extraction patent. PAOG aims to develop both pharmaceutical and nutraceutical treatments based on this intellectual property, enhancing its market presence.